Sanofi could name Bayer's Olivier Brandicourt as new chief executive, sources say

16 February 2015

Sources say that Olivier Brandicourt, the current head of healthcare at German drug major Bayer (BAYN: DE), is the leading candidate to become the new chief executive at Sanofi (Euronext: SAN), replacing Christopher Viehbacher.

Sanofi’s chairman Serge Weinberg has been serving as acting chief executive since Mr Viehbacher’s ousting in October said the company plans to name its new chief executive this quarter, and that it would be looking outside the company to fill the appointment.

The sources suggested that discussions around Mr Brandicourt’s departure from the German drugmaker are underway and largely depend on wrapping up contractual obligations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK